Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polymyxin b sulfate + bacitracin zinc + neomycin
- Development stage
- Approved
- Lead developer
- Bausch + Lomb
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
Polymyxin b sulfate + bacitracin zinc + neomycin is a **topical ophthalmic triple-antibiotic combination** used for the treatment of superficial bacterial infections of the external eye and its adnexa, including conjunctivitis, keratitis, keratoconjunctivitis, blepharitis, and blepharoconjunctivitis caused by susceptible organisms. The ointment combines three small-molecule antibiotics with complementary antibacterial spectra: polymyxin B disrupts the cell membrane of susceptible gram-negative bacteria, neomycin is an aminoglycoside that inhibits bacterial protein synthesis, and bacitracin inhibits bacterial cell wall synthesis with primary activity against gram-positive organisms. It has been marketed as ophthalmic ointment products including Neo-Polycin and Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, and the provided context identifies Bausch & Lomb as a developer/marketer.
- Brand names
- Neo-PolycinNeomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment
- Other names
- polymyxin b sulfate + bacitracin zinc + neomycinneomycin and polymyxin b sulfates and bacitracin zinc ophthalmic ointmenttriple-antibiotic ophthalmic ointment
02
Targets
Bacterial RibosomeUP (Undecaprenyl phosphate)Neuraminidase
Beyond the preview
Go deeper on polymyxin b sulfate + bacitracin zinc + neomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polymyxin b sulfate + bacitracin zinc + neomycin.